Production (Stage)
Arrowhead Pharmaceuticals, Inc.
ARWR
$15.13
-$0.26-1.69%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 314.02% | -1.49% | 0.15% | -36.31% | 5.69% |
| Total Depreciation and Amortization | 16.22% | 4.18% | 5.08% | 5.68% | 6.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 30.95% | 42.64% | -21.60% | 3.67% | 15.70% |
| Change in Net Operating Assets | 711.90% | -193.56% | -67.73% | 631.71% | 130.98% |
| Cash from Operations | 414.52% | -6.60% | -18.89% | -24.94% | 21.61% |
| Capital Expenditure | 29.52% | 69.06% | -68.10% | 57.60% | 50.37% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -591.46% | 142.50% | -1,028.28% | 109.11% | -275.93% |
| Cash from Investing | -646.37% | 134.50% | -3,307.99% | 102.58% | -514.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 38,386.91% | 184.30% | -42.38% | -99.91% | 161,239.70% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -100.00% | 738.16% | -106.27% | -- | -- |
| Cash from Financing | 347.72% | -94.70% | 672.20% | -88.30% | 161,239.70% |
| Foreign Exchange rate Adjustments | -491.18% | -101.57% | 2,044.39% | -957.69% | -55.17% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 370.15% | -246.60% | 157.09% | -183.91% | 231.92% |